SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
________________
Form
8-K
________________
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
January
14, 2008
Date
of Report
(Date
of earliest event reported)
________________
A.P.
PHARMA, INC.
(Exact
name of Registrant as specified in its charter)
________________
|
Delaware
|
000-33221
|
94-2875566
|
||
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
123
Saginaw Drive
Redwood
City, California 94063
(Address
of principal executive offices) (Zip code)
(650)
366-2626
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
________________
Item
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On
January 14, 2008, A.P. Pharma, Inc.,
a Delaware corporation (the “Company”), issued a press release, attached hereto
as Exhibit 99.1 to this Form 8-K, announcing that Michael O’Connell, Chief
Financial Officer of the Company, is leaving the Company on January 18,
2008. Mr. O’Connell will continue to act as the Company’s principal
financial officer and principal accounting officer until his
departure. Following that, Gregory Turnbull, President and Chief
Executive Officer of the Company, will serve as principal financial officer
and
principal accounting officer on an interim basis until a successor is
appointed. The Company will commence a search for a new Chief
Financial Officer.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits
99.1
Press Release of A.P. Pharma, Inc. dated January 14, 2008
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
A.P.
PHARMA, INC.
|
||||
|
Date:
January 15, 2008
|
By:
|
/s/
Gregory Turnbull
________________
|
||
|
Name:
Gregory Turnbull
|
||||
|
Title: President
and Chief Executive Officer
|
||||
News
Release
A.P.
PHARMA ANNOUNCES EXECUTIVE OFFICER DEPARTURE
REDWOOD
CITY, Calif. (January 14,
2008) – A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals
company, announced
today that Michael O’Connell, its Chief Operating Officer and Chief Financial
Officer, will be leaving the company on January 18, 2008. Mr.
O’Connell originally joined A.P. Pharma in 1992 as Vice President and Chief
Financial Officer. In 2000 he was named President and Chief Executive
Officer, and served in that capacity until departing in October of 2006 on
medical leave. He rejoined the management team in mid-2007 in his
present capacity. Upon his resignation, Mr. O’Connell will be
entitled to the benefits of a retention agreement that are payable due to his
not being reappointed to the position of President and Chief Executive
Officer.
The
company will be conducting
a search for a new Chief
Financial Officer. Until a successor is engaged Gregory Turnbull, the
company’s current President and Chief Executive Officer, will also handle the
duties of the Chief Financial Officer on an interim basis.
About
A.P. Pharma
A.P.
Pharma is a specialty pharmaceutical company focused on the development of
ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based
drug delivery systems. The Company's primary focus is the development and
commercialization of its bioerodible injectable and implantable systems under
the trade name Biochronomer™. Initial target areas of application for the
Company's drug delivery technology include anti-nausea, pain management,
anti-inflammation and DNA/RNAI applications. For further information visit
the
Company's web site at www.appharma.com.
|
Investor
Relations Contacts:
|
Company
Contact:
|
|
Lippert/Heilshorn
& Associates
|
Gregory
Turnbull
|
|
Don
Markley (dmarkley@lhai.com)
|
President
and Chief Executive Officer
|
|
(310)
691-7100
|
(650)
366-2626
|